Answers are grounded in this paper and cite their sources.
The burden of urinary tract infections (UTIs) is high in both industrialized and developing countries. As causative therapies of these frequently recurring infections have substantial limits, preventive measures deserve priority. Among these, immunostimulation with bacterial extracts has been shown to prevent recurrent UTIs and to be very safe. The aim of this review is to focus on the immunostimulating agent OM-89, a biotechnology-derived lyophilized extract from Escherichia coli, a germ frequently responsible for UTIs, and formulated for oral administration. This review will cover its pharmacological effects and its actions in clinical practice with respect to both efficacy and safety. A particular emphasis will be put on clinical trials conducted in children, adults and special patient populations as well as on a survey assessing the effect of OM-89 on the patients’ quality of life.
No takes yet. Share an insight, caveat, or question.
Meredith et al. (2009) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: